Comparative Pharmacology
Head-to-head clinical analysis: ANDROGEL versus HALOTESTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROGEL versus HALOTESTIN.
ANDROGEL vs HALOTESTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
None Documented
None Documented
The terminal elimination half-life of testosterone from AndroGel is approximately 10-12 hours when applied topically, but due to continuous absorption from the skin depot, serum levels are sustained over 24 hours, allowing once-daily dosing.
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Approximately 90% of a topical dose is excreted in urine as conjugated and unconjugated metabolites, with about 6% excreted in feces via bile; renal elimination is the primary route.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Category C
Category C
Androgen
Androgen